What was the growth in revenue and EBITDA for FY26?

Jubilant Pharmova recorded revenue of ₹8,280 crore, a 14% increase, while EBITDA rose 8% to ₹1,326 crore.

What operational updates did the company provide?

The company successfully onboarded a new oncology product on its Line 3 facility and continues to work on remediation at its Montreal site.

Does this filing contain any unexpected financial data?

No. The financial figures were anticipated by the market and are consistent with standard reporting.

Earnings · CDMO · Mid cap

Jubilant Pharmova posts 14% revenue growth in FY26

The company reported annual revenue of ₹8,280 crore and EBITDA of ₹1,326 crore, marking an 8% increase over the prior year.

— 7 earlier stories on Jubilant Pharmova Ltd. →

JUBLPHARMA By Tipsheet Editorial 22 May 2026 · 2:54 PM IST Verify on BSE · NSE

Mkt cap₹15,848 cr

P/E39.77×

ROE13.42%

Debt / eq.0.39

Div yld0.50%

₹8,280 cr Total revenue for FY26, representing 14% year-on-year growth.

What's new

FY26 revenue reached ₹8,280 cr, up 14% from the previous year.
EBITDA grew 8% to reach ₹1,326 cr for the full year.
The company onboarded a new oncology product on its Line 3 facility.

Why this matters

These results align with market expectations and offer no surprises to alter existing investment models. The focus remains on operational execution, specifically the ongoing remediation efforts at the Montreal facility.

What we're watching

Progress on Montreal facility remediation.
Utilization rates for the new oncology product on Line 3.
Margin stability in the coming quarters.

The full read

Jubilant Pharmova closed FY26 with ₹8,280 crore in revenue, a 14% increase over the prior year. EBITDA followed with 8% growth, reaching ₹1,326 crore. Beyond the headline financials, the company confirmed the onboarding of a new oncology product on its Line 3 facility and provided updates on its Montreal remediation efforts. This is a routine earnings release. The figures were widely anticipated by the market and provide no material surprises to shift current investment theses. The company's performance remains steady, with management focused on operational milestones rather than structural changes. For investors, the data confirms a predictable trajectory for the business.

Questions answered

What was the growth in revenue and EBITDA for FY26?: Jubilant Pharmova recorded revenue of ₹8,280 crore, a 14% increase, while EBITDA rose 8% to ₹1,326 crore.
What operational updates did the company provide?: The company successfully onboarded a new oncology product on its Line 3 facility and continues to work on remediation at its Montreal site.
Does this filing contain any unexpected financial data?: No. The financial figures were anticipated by the market and are consistent with standard reporting.

Mentioned: Jubilant Pharmova · Montreal facility · Line 3

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on JUBLPHARMA →

22 May 2026 · 2:54 PM IST Jubilant Pharmova posts 14% revenue growth in FY26
1d ago Jubilant's Montreal plant gets a USFDA warning. New approvals are frozen.
3d ago Jubilant Pharmova targets 18% margins as Spokane facility gains speed
8d ago Jubilant Pharmova subsidiary lands ₹107.89 cr tax demand
8d ago Jubilant Pharmova pulls Spokane Line 3 timeline forward by two years